CBPO  China Biologic Products Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

3.25B

Vuru Grade

72.45/100

Current Price

$120.93
-5.16 (-4.09%)

Growth Price

$39.27
Overvalued by 67.53%

Stability Price

$21.87
Overvalued by 81.91%

Company Metrics

  • P/E 34.87
  • P/S 10.46
  • P/B 7.64
  • EPS 3.47
  • Cash ROIC 27.80%
  • Cash Ratio 2.02
  • Dividend 0 / 0%
  • Avg. Vol. 227,980.00
  • Shares 26.88M
  • Market Cap. 3.25B

Company Description

China Biologic Products, Inc., a biopharmaceutical company, engages in the research, development, production, and manufacture of plasma-based pharmaceutical products in the People's Republic of China. It offers Human Albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Stock Chart to Observe: Could China Biologic Products Inc Change Direction ...
Chester News - 12 hours ago
The stock of China Biologic Products Inc (CBPO) formed H&SI with $191.07 price target or 58.00% above the current $120.93 share price.
10 Biotechnology Stocks to Buy Now - Investorplace.com
Notable Pattern Reporting: Could China Biologic Products Inc Go Up? The Stock ...
Chester News - Sep 16, 2016
The stock of China Biologic Products Inc (CBPO) formed H&SI with $149.27 price target or 22.00% above the current $122.35 share price.
China Biologic Products Inc (CBPO) Downgraded by Zacks Investment Research to ... - DailyQuint
China Biologic Products Inc. (CBPO) Position Maintained by British Airways ...
Community Financial News - Sep 23, 2016
China Biologic Products logo British Airways Pensions Investment Management Ltd held its stake in China Biologic Products Inc. (NASDAQ:CBPO) during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional ...
Changes To China Biologic Products, Inc. (NASDAQ:CBPO) Target Prices - Fiscal Standard
China Biologic Products Inc versus Opko Health Inc Head to Head Compare
CML News - Sep 6, 2016
China Biologic Products Inc has a higher fundamental rating than Opko Health Inc which has an impact on the head-to-head comparison.
Spq Asia Capital Ltd adds China Biologic Products Inc (CBPO) to its portfolio - Market Digest
Ariad Pharmaceuticals Inc versus China Biologic Products Inc Head to Head Compare
CML News - Sep 2, 2016
China Biologic Products Inc has a substantially higher fundamental rating then Ariad Pharmaceuticals Inc which has an impact on the head-to-head comparison.
China Biologic Products Inc versus Emergent BioSolutions Inc Head to Head Compare
CML News - Aug 31, 2016
China Biologic Products Inc has a higher fundamental rating than Emergent BioSolutions Inc which has an impact on the head-to-head comparison.
Harvard Management Co Inc Lowers stake in China Biologic Products Inc (CBPO) - TheFounders Daily
Ativo Capital Management buys $11819457 stake in China Biologic Products Inc ... - Trade Calls
Option Market: China Biologic Products Inc Risk Hits A Lowered Level
CML News - Sep 1, 2016
This is a proprietary risk rating for the next 30-days built by Capital Market Laboratories (CMLviz) based on a large number of interactions of data points, many of which come directly from the option market for China Biologic Products Inc (NASDAQ:CBPO) .
China Biologic Products Inc versus Eagle Pharmaceuticals Inc Head to Head Compare
CML News - Sep 20, 2016
China Biologic Products Inc has a higher fundamental rating than Eagle Pharmaceuticals Inc which has an impact on the head-to-head comparison.
Traders Are Watching: Control4 Corporation (NASDAQ:CTRL), China Biologic ...
Benchmark Monitor - Sep 26, 2016
Control4 Corporation (NASDAQ:CTRL) traded 1.86 Million shares on last trading day with closing price of $11.87. Company gross margin stands at 49.30% whereas its return on investment (ROI) is -0.90%.
China Biologic Products (CBPO) Unit Receives China FDA Approval to Begin Human ...
StreetInsider.com - Sep 19, 2016
China Biologic Products, Inc. (Nasdaq: CBPO) announced that Shandong Taibang Biological Products Co. Ltd., the Company's majority-owned subsidiary, recently obtained approval from the China Food and Drug Administration (the "CFDA") to begin human ...
Analyst Revises China Biologic Products, Inc. (NASDAQ:CBPO) Stock Target To ... - Equities Focus